Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P859: ANTI-CD38 NANOBODY JK36...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS

P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS

Bibliographic Details
Main Authors: E. Meseguer Martinez, J. Marco Buades, A. García Feria, P. Ribas García, M. J. Fernandez Llavador, A. López Gabaldon, S. Broseta Tormos, E. Francés Aracil, O. Cortés Ortega, E. Donato Martínez, M. Fernandez Zarzoso, M. Panero Ruiz, M. J. Cejalvo Andújar, A. Tolosa Muñoz, M. L. Juan Marco, D. Ivars Santacreu, E. Gómez Beltrán, M. J. Sayas Lloris
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000846316.26911.4d
  • Holdings
  • Description
  • Similar Items
  • Staff View
Description
ISSN:2572-9241

Similar Items

  • P1527: NEXT GENERATION SEQUENCING IN HEREDITARY SPHEROCYTOSIS DIAGNOSIS
    by: A. García Feria, et al.
    Published: (2022-06-01)
  • The JK System to Detect Plagiarism
    by: Khair Eddin M. Sabri, et al.
    Published: (2006-10-01)
  • PHOTOMETRICAL STUDY OF OVERCONTACT BINARY SYSTEM V859Cyg
    by: E. A. Panko, et al.
    Published: (2016-10-01)
  • P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
    by: F. B. Askeland, et al.
    Published: (2022-06-01)
  • MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    by: Manisha Bhutani, et al.
    Published: (2025-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs